| pubmed-article:19439014 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19439014 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:19439014 | lifeskim:mentions | umls-concept:C0439640 | lld:lifeskim |
| pubmed-article:19439014 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:19439014 | lifeskim:mentions | umls-concept:C0033268 | lld:lifeskim |
| pubmed-article:19439014 | lifeskim:mentions | umls-concept:C1710360 | lld:lifeskim |
| pubmed-article:19439014 | lifeskim:mentions | umls-concept:C0079411 | lld:lifeskim |
| pubmed-article:19439014 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:19439014 | pubmed:dateCreated | 2009-5-14 | lld:pubmed |
| pubmed-article:19439014 | pubmed:abstractText | We previously demonstrated that dendritic cells (DC) that have endocytosed apoptotic bodies of autologous leukemic cells (Apo-DC) can boost antileukemic T-cell responses. In this study, we report a description of the production procedure and product specification of the Apo-DC vaccine preparations for clinical use. Enriched populations of CD14+ monocytic precursors and CD19+ leukaemic cells were obtained using CliniMACS technology from a single leukapheresis product. Apoptotic bodies were obtained by irradiating (5 Gy) CD19+ selected B cells. DC were generated ex vivo by culturing monocytes with granulocyte macrophage colony-stimulating factor and interleukin-4. Following coculture with apoptotic bodies, DCs were matured with tumour necrosis factor-alpha. The mean percentage of CD14+ cells in the peripheral blood as well as in the leukapheresis product of the patients (n = 10) was approximately 2% (range, 0.8-3.3). Immunomagnetic selection using the CD14 reagent yielded a CD14+ population that was 91 +/- 2.2% (mean +/- SEM) pure. Immunomagnetic selection of CD19 expressing cells yielded a population that was 100 +/- 0.03% pure. Cell viability immediately after selection was 97% and 98% after 7 days of culture. The Apo-DC cellular vaccine product showed a mature phenotype, with a high rate of endocytosis (84%) of apoptotic leukemic B-cells. In conclusion, despite significant variability in the circulating monocyte frequency of the chronic lymphocytic leukaemia patients, our method permitted the production of a DC vaccine with high reproducibility and conforming with recommended quality standards. | lld:pubmed |
| pubmed-article:19439014 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19439014 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19439014 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19439014 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19439014 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19439014 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19439014 | pubmed:issn | 1365-3083 | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:HanssonLL | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:MellstedtHH | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:ErikssonII | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:HanssonMM | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:AdamsonLL | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:ChoudhuryAA | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:PalmaMM | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:Näsman-Glaser... | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:OsterborgAA | lld:pubmed |
| pubmed-article:19439014 | pubmed:author | pubmed-author:KokhaeiPP | lld:pubmed |
| pubmed-article:19439014 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19439014 | pubmed:volume | 69 | lld:pubmed |
| pubmed-article:19439014 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19439014 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19439014 | pubmed:pagination | 529-36 | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:meshHeading | pubmed-meshheading:19439014... | lld:pubmed |
| pubmed-article:19439014 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19439014 | pubmed:articleTitle | Generation of a dendritic cell-based vaccine in chronic lymphocytic leukaemia using CliniMACS platform for large-scale production. | lld:pubmed |
| pubmed-article:19439014 | pubmed:affiliation | Immune and Gene Therapy Laboratory, Department of Oncology & Pathology, Cancer Centre Karolinska, Stockholm, Sweden. | lld:pubmed |
| pubmed-article:19439014 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19439014 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:19439014 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
